Effects of Atorvastatin Versus Probucol on Small Dense LDL

This study has been completed.
Sponsor:
Information provided by:
Yokohama City University Medical Center
ClinicalTrials.gov Identifier:
NCT00276133
First received: January 11, 2006
Last updated: May 8, 2007
Last verified: May 2007
  Purpose

Small dense low-density lipoprotein (LDL) plays an important role in causing glomerular injury through conversion to an oxidatively modified form of LDL. However, few studies evaluated the effects of antilipidemic agents on the LDL particle size and renoprotective actions in hyperlipidemic patients with non-diabetic nephropathy.


Condition Intervention Phase
Chronic Nephropathy
Drug: Effects of atorvastatin versus probucol on small dense LDL
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy

Resource links provided by NLM:


Further study details as provided by Yokohama City University Medical Center:

Primary Outcome Measures:
  • Normalization of serum cholesterol concentrations [ Time Frame: One year ]

Enrollment: 24
Study Start Date: January 2004
Study Completion Date: May 2007
Detailed Description:

The study is a randomized crossover trial comparing the effect of atorvastatin (10 mg/day) and probucol (500 mg/day) for 24 weeks in 30 patients (urinary albumin excretion 0.3–2.0 g/day, and creatinine clearance > 30 ml/min/1.73 m2 or serum creatinine concentration < 2 mg/L). Lipid parameters, mean LDL particle diameter, creatinine clearance, and urinary albumin to creatinine excretion ratio are measured before and during treatment periods. It will be evaluated that, first, whether atorvastatin and probucol significantly reduce serum total cholesterol and LDL cholesterol concentrations, second, whether atorvastatin and probucol significantly increase the LDL particle size, third, whether significant differences in urinary albumin/creatinine excretion ratio and creatinine clearance are observed in both groups during treatment.

  Eligibility

Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hyperlipidemic patients with non-diabetic nephropathy

Exclusion Criteria:

  • Endocrinological, hematological or hepatic disease
  • Cerebral infarction or hemorrhage
  • Homozygous familial hypercholesterolemia
  • Uncontrolled hypertension
  • Myocardial infarction occurring within the previous 6 months
  • Unstable angina
  • Diabetic nephropathy
  • Abnormal thyroid function
  • Receiving steroids or immunosuppressive agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00276133

Locations
Japan
Yokohama City University Center Hospital
Yokohama, Kanagawa, Japan, 232-0024
Sponsors and Collaborators
Yokohama City University Medical Center
Investigators
Principal Investigator: Gen Yasuda, MD Yokohama City University Center Hospital
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00276133     History of Changes
Other Study ID Numbers: 7332-1
Study First Received: January 11, 2006
Last Updated: May 8, 2007
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Yokohama City University Medical Center:
small dense LDL

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases
Probucol
Atorvastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses
Antioxidants
Protective Agents
Physiological Effects of Drugs
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on July 24, 2014